Royalty Pharma plc Operating Income
Royalty Pharma plc (RPRX) reported Operating Income of $133.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Royalty Pharma plc operating income (loss) for the quarter ending 2026-06-30 was $133.12M, a 36.55% decline year-over-year.
- Royalty Pharma plc operating income (loss) for the quarter ending 2026-03-31 was $563.04M, a 5.40% increase year-over-year.
- Royalty Pharma plc operating income (loss) for the quarter ending 2025-12-31 was $388.38M, a 7.43% increase year-over-year.
- Royalty Pharma plc operating income (loss) for the quarter ending 2025-09-30 was $427.16M, a 41.89% decline year-over-year.
- Royalty Pharma plc operating income (loss) for fiscal 2025 was $1.56B, a 20.66% increase from fiscal 2024.
- Royalty Pharma plc operating income (loss) for fiscal 2024 was $1.29B, a 13.38% decline from fiscal 2023.
- Royalty Pharma plc operating income (loss) for fiscal 2023 was $1.49B, a 385.94% increase from fiscal 2022.
- Royalty Pharma plc operating income (loss) for fiscal 2022 was $307.06M, a 78.54% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $133.12M 10-Q · filed 2026-08-05 | $696.16M 10-Q · filed 2026-08-05 | $1.08B derived: sum of 3 quarters · filed 2026-08-05 | $1.51B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $563.04M 10-Q · filed 2026-05-06 | $951.42M derived: sum of 2 quarters · filed 2026-05-06 | $1.38B derived: sum of 3 quarters · filed 2026-05-06 | $1.59B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $388.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $815.54M derived: sum of 2 quarters · filed 2026-02-11 | $1.03B derived: sum of 3 quarters · filed 2026-08-05 | $1.56B 10-K · filed 2026-02-11 |
| 2025-09-30 | $427.16M 10-Q · filed 2025-11-05 | $636.96M derived: sum of 2 quarters · filed 2026-08-05 | $1.17B 10-Q · filed 2025-11-05 | $1.53B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $209.80M 10-Q · filed 2026-08-05 | $743.98M 10-Q · filed 2026-08-05 | $1.11B derived: sum of 3 quarters · filed 2026-08-05 | $1.84B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $534.18M 10-Q · filed 2026-05-06 | $895.70M derived: sum of 2 quarters · filed 2026-05-06 | $1.63B derived: sum of 3 quarters · filed 2026-05-06 | $1.90B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $361.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.10B derived: sum of 2 quarters · filed 2026-02-11 | $1.37B derived: sum of 3 quarters · filed 2026-02-11 | $1.29B 10-K · filed 2026-02-11 |
| 2024-09-30 | $735.07M 10-Q · filed 2025-11-05 | $1.00B derived: sum of 2 quarters · filed 2025-11-05 | $930.93M 10-Q · filed 2025-11-05 | $1.54B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $269.63M 10-Q · filed 2025-08-06 | $195.86M 10-Q · filed 2025-08-06 | $808.75M derived: sum of 3 quarters · filed 2026-02-11 | $960.19M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$73.77M 10-Q · filed 2025-05-08 | $539.12M derived: sum of 2 quarters · filed 2026-02-11 | $690.56M derived: sum of 3 quarters · filed 2026-02-11 | $939.40M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $612.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $764.34M derived: sum of 2 quarters · filed 2026-02-11 | $1.01B derived: sum of 3 quarters · filed 2026-02-11 | $1.49B 10-K · filed 2026-02-11 |
| 2023-09-30 | $151.44M 10-Q · filed 2024-11-06 | $400.28M derived: sum of 2 quarters · filed 2024-11-06 | $879.25M 10-Q · filed 2024-11-06 | $396.60M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $248.84M 10-Q · filed 2024-08-08 | $727.81M 10-Q · filed 2024-08-08 | $245.16M derived: sum of 3 quarters · filed 2025-02-12 | $437.37M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $478.97M 10-Q · filed 2024-05-09 | -$3.68M derived: sum of 2 quarters · filed 2025-02-12 | $188.53M derived: sum of 3 quarters · filed 2025-02-12 | $566.32M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$482.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$290.44M derived: sum of 2 quarters · filed 2025-02-12 | $87.35M derived: sum of 3 quarters · filed 2025-02-12 | $307.06M 10-K · filed 2025-02-12 |
| 2022-09-30 | $192.21M 10-Q · filed 2023-11-08 | $570.00M derived: sum of 2 quarters · filed 2023-11-08 | $789.72M 10-Q · filed 2023-11-08 | $943.14M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $377.79M 10-Q · filed 2023-08-08 | $597.51M 10-Q · filed 2023-08-08 | $750.93M derived: sum of 3 quarters · filed 2024-02-15 | $1.05B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $219.72M 10-Q · filed 2023-05-09 | $373.13M derived: sum of 2 quarters · filed 2024-02-15 | $676.19M derived: sum of 3 quarters · filed 2024-02-15 | $1.42B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $153.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $456.47M derived: sum of 2 quarters · filed 2024-02-15 | $1.20B derived: sum of 3 quarters · filed 2024-02-15 | $1.43B 10-K · filed 2024-02-15 |
| 2021-09-30 | $303.05M 10-Q · filed 2022-11-08 | $1.05B derived: sum of 2 quarters · filed 2022-11-08 | $1.28B 10-Q · filed 2022-11-08 | $1.59B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $744.95M 10-Q · filed 2022-08-04 | $974.25M 10-Q · filed 2022-08-04 | $1.29B derived: sum of 3 quarters · filed 2023-02-15 | $1.80B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $229.30M 10-Q · filed 2022-05-05 | $543.35M derived: sum of 2 quarters · filed 2023-02-15 | $1.05B derived: sum of 3 quarters · filed 2023-02-15 | $1.46B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $314.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $824.62M derived: sum of 2 quarters · filed 2023-02-15 | $1.23B derived: sum of 3 quarters · filed 2023-02-15 | $1.60B 10-K · filed 2023-02-15 |
| 2020-09-30 | $510.57M 10-Q · filed 2021-11-10 | $919.91M derived: sum of 2 quarters · filed 2021-11-10 | $1.28B 10-Q · filed 2021-11-10 | $2.61B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $409.35M 10-Q · filed 2021-08-11 | $770.78M 10-Q · filed 2021-08-11 | $2.10B derived: sum of 3 quarters · filed 2022-02-15 | $2.64B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $361.43M 10-Q · filed 2021-05-11 | $1.69B derived: sum of 2 quarters · filed 2022-02-15 | $2.23B derived: sum of 3 quarters · filed 2022-02-15 | $2.55B derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $1.33B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $1.86B derived: sum of 2 quarters · filed 2022-02-15 | $2.19B derived: sum of 3 quarters · filed 2022-02-15 | $2.62B 10-K · filed 2022-02-15 |
| 2019-09-30 | $532.50M 10-Q · filed 2020-11-12 | $860.36M derived: sum of 2 quarters · filed 2020-11-12 | $1.29B 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $327.86M 10-Q · filed 2020-08-12 | $758.76M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $1.36B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |